Vyant Bio, Inc. Common Stock
VYNT
VYNT was delisted on the 12th of May, 2023.
12 hedge funds and large institutions have $694K invested in Vyant Bio, Inc. Common Stock in 2020 Q2 according to their latest regulatory filings, with 2 funds opening new positions, 1 increasing their positions, 4 reducing their positions, and 3 closing their positions.
16% more capital invested
Capital invested by funds: $597K → $694K (+$97K)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
8% less funds holding
Funds holding: 13 → 12 (-1)
33% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 3
75% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 4
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$39.2K |
| 2 |
Acadian Asset Management
Boston,
Massachusetts
|
+$10.5K |
| 3 |
CAPTRUST Financial Advisors
Raleigh,
North Carolina
|
+$546 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
-$4.79K |
| 2 |
FPB
First PREMIER Bank
Sioux Falls,
South Dakota
|
-$3K |
| 3 |
Victory Capital Management
San Antonio,
Texas
|
-$2K |
| 4 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
-$640 |
| 5 |
Osaic Holdings
Scottsdale,
Arizona
|
-$250 |
VYNT Hedge Fund Activity: Q2 2020 in Review
12 of the 4,877 institutional investors tracked by Wall St. Rank reported a position in Vyant Bio, Inc. Common Stock (VYNT) for Q2 2020, worth a combined $694K — up 16% from $597K a quarter earlier.
Sellers outnumbered buyers: 3 funds closed out of VYNT and 2 opened new positions — a net loss of 1 holder — while 4 trimmed existing stakes and 1 added.
The largest buyer was Renaissance Technologies, adding an estimated $39.2K. The largest seller was UBS Group, cutting an estimated $4.79K.
- 12 institutional investors held Vyant Bio, Inc. Common Stock (VYNT) as of Q2 2020, down from 13 in Q1 2020.
- Funds reported $694K of Vyant Bio, Inc. Common Stock stock for Q2 2020, up 16% quarter-over-quarter.
- 2 funds opened new Vyant Bio, Inc. Common Stock positions in Q2 2020 and 3 closed out, a net change of -1 holder.
- The largest Vyant Bio, Inc. Common Stock buyer in Q2 2020 was Renaissance Technologies, an estimated $39.2K added.
- The largest Vyant Bio, Inc. Common Stock seller in Q2 2020 was UBS Group, an estimated $4.79K sold.
Based on aggregated 13F filings for Q2 2020.